CD44 and Miyoshi myopathy: Canella et al. reported that the pan-histone deacetylase inhibitor AR-42 downregulated CD44 expression and enhanced the anti-MM activity of lenalidomide in primary MM cells isolated from lenalidomide-resistant patients and cells isolated from an in vivo MM mouse model [42].